GC
KLRS

GMT Capital’s Kalaris Therapeutics KLRS Stock Holding History

GMT Capital’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-183,099
Closed -$9.05M – 101
2023
Q3 		$9.05M Buy
183,099
+4,661
+3% +$318K 0.34% 44
2023
Q2 		$14M Buy
178,438
+33,497
+23% +$3.18M 0.53% 33
2023
Q1 		$13.1M Buy
144,941
+24,991
+21% +$3.18M 0.52% 35
2022
Q4 		$14.2M Hold
119,950
– – 0.65% 37
2022
Q3 		$21.8M Buy
119,950
+37,725
+46% +$5.88M 1.35% 24
2022
Q2 		$7.38M Buy
82,225
+32,744
+66% +$3.43M 0.47% 41
2022
Q1 		$7.68M Buy
49,481
+20,274
+69% +$4.04M 0.48% 37
2021
Q4 		$8.69M Buy
29,207
+8,490
+41% +$3.94M 0.67% 28
2021
Q3 		$11.9M Buy
+20,717
New +$9.6M 1.05% 22

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

GMT Capital's KLRS Position: Q4 2023 in Review

GMT Capital sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 183,099 shares — an estimated $9.05M sold.

GMT Capital first reported a position in KLRS in Q3 2021 and held it in 9 quarters. The position peaked at $21.8M in Q3 2022. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • GMT Capital reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • GMT Capital sold 183,099 Kalaris Therapeutics shares in Q4 2023, an estimated $9.05M.
  • GMT Capital first reported a position in Kalaris Therapeutics in Q3 2021 and held it in 9 quarters.
  • GMT Capital's Kalaris Therapeutics position peaked at $21.8M in Q3 2022.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on GMT Capital's 13F filing for Q4 2023, filed 12 Feb 2024.